Safety Profile & Considerations In preclinical research, BPC-157 has demonstrated a remarkably high safety threshold
Here's the honest, evidence-based answer, and who really benefits from them
This is relevant, as platelets are the first cells that arrive at a site of injury to release various factors that initiate the repair process
We also need to watch for any side effects
We note that, on an annual basis, based on our analysis of the latest claims data, we identify violations to the 2 times rule and propose changes when appropriate
Native rhIGF-1 (mecasermin, brand name Increlex) is FDA-approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralizing antibodies to GH